5440092026-04-012026-06-305440092026-04-012026-06-30in-capmkt:OtherExpenses1Memberiso4217:INRiso4217:INRxbrli:shares544009BLUEJETNOTLISTEDINE0KBH01020BLUE JET HEALTHCARE LIMITEDMain BoardEquity2026-04-012027-03-312026-08-032026-07-28INRMillionsQuarterlyFirst quarterSingle segmentPharmaceutical and API'S2026-08-0312:10:002026-08-0312:27:00Not applicablefalsefalseThere is no requirement of disclosure on loans and debt securities as it is not applicable2026-04-012026-06-30UnauditedStandalone2931130000152370000308350000017887800000-41767000020117000066000006706000037810000020240400001059460000010594600002650000001182000027682000007826400000000782640000078264000034693000024.514.51004.514.511. The above financial results of the Company for the three months ended June 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 03, 2026. 2. Further, the above financial results have been reviewed by the Statutory Auditor of the Company. <br /> 2. The company is engaged in manufacturing of Artificial Sweetener, Contrast Media Intermediate, Pharma Intermediate, APIs used in Pharmaceutical and Healthcare products and the same constitutes a single reportable business segment as per IND AS 108. <br /> 3. The results for the three months ended March 31, 2026 are balancing figure between the audited financial statements for the financial year ended March 31, 2026 and published unaudited results for nine months ended December 31, 2025. <br /> 4. Subsequent to the quarter ended June 30, 2026, the Company allotted 1,58,10,276 equity shares of face value of Rs. 2 each to the eligible Qualified Institutional Buyers (QIB), at the issue price of Rs. 506 per equity share (including a premium of Rs. 504 per equity share), aggregating to Rs. 8,000.00 million, pursuant to Qualified Institutional Placement (QIP) in accordance with the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations (the “SEBI ICDR Regulations”). <br /> 5. The Company does not have any subsidiaries, associates, or joint ventures as on June 30, 2026. Consequently, the preparation of consolidated financial statements is not applicable. <br /> Other Operating Expenses378100000000